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Background: Yukmijihwang-tang, a traditional herbal formula, has been used for treating disorder, diabetic mellitus
and neurosis in China (Liu-wei-di-huang-tang in Chinese), Japan (Lokumijio-to in Japanese) and Korea for many
years. In this study, we investigated the effects of Yukmijihwang-tang water extract (YJT) on the development of
benign prostatic hyperplasia (BPH) using a rat model of testosterone propionate (TP)-induced BPH.
Methods: A total of 30 rats were divided into five groups. One group was used as a control and the other groups
received subcutaneous injections of TP for 4 weeks to induce BPH. YJT (200 or 400 mg/kg) was administered daily
for 4 weeks to two groups by oral gavage concurrently with the TP. The animals were euthanized, the prostate and
body weights were recorded, and tissues were subjected to hormone assays and histomorphology. In addition, we
investigated proliferating cell nuclear antigen (PCNA) expression in the prostate using immunoblotting.
Results: Animals with BPH showed significantly increased absolute and relative prostate weights, increased
dihydrotestosterone levels in the serum or prostate and increased PCNA expression in the prostate; however,
YJT-treated animals showed significant reductions compared with the animals with TP-induced BPH.
Histomorphology also showed that YJT inhibited TP-induced prostatic hyperplasia.
Conclusions: These findings indicate that YJT effectively inhibited the development of BPH and might be a useful
drug clinically.
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Benign prostate hyperplasia (BPH) is a urological dis-
order caused by the noncancerous enlargement of the
prostate as men age. As the prostate enlarges, it can
constrict the urethra, inducing various symptoms includ-
ing a weak urinary stream, incomplete bladder emptying,
nocturia, dysuria and bladder outlet obstruction [1,2].
These symptoms associated with BPH are known as
lower urinary tract symptoms (LUTS) [3]. Currently, the
two main medications used for treatment of BPH are α1-
adrenergic receptor antagonists and 5α-reductase inhibi-
tors [4]. The α1-adrenergic receptor antagonists, includ-
ing doxazosin, terazosin and tamsulosin, are the initial* Correspondence: hkshin@kiom.re.kr
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reproduction in any medium, provided the ordrugs for treating BPH, and they alleviate LUTS by re-
laxation of smooth muscle in the prostate and the neck
of the bladder [5,6]. On the other hand, the 5α-
reductase inhibitors inhibit the development of BPH via
a reduction in dihydrotestosterone (DHT) production
[7]. In the development of BPH, 5α-reductase catalyzes
the conversion of testosterone to DHT, which induces
an increase in the DHT level in the prostate. This accel-
erates hyperplasia of the stromal and epithelial cells of
the prostate, resulting in prostatic enlargement [8]. As
mentioned above, α1-adrenergic receptor antagonists
and 5α-reductase inhibitors are effective in treating men
with BPH. However, these drugs are limited because of
their side effects, including decreased libido, ejaculatory
or erectile dysfunction, and nasal congestion [9,10].
Yukmijihwang-tang (Liu-wei-di-huang-tang in Chinese;
Lokumijio-to in Japanese), an oriental herbal formula, hasd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Shin et al. BMC Complementary and Alternative Medicine 2012, 12:48 Page 2 of 7
http://www.biomedcentral.com/1472-6882/12/48been used for many years in Korea, China and Japan. It
is composed of six herbs: Rehmannia glutinosa, Cornus
officinalis, Dioscorea batatas, Paeonia suffruticosa, Poria
cocos, Alisma orientale. In particular, Yukmijihwang-tang
is one of the most widely used herbal formulas in Korea
and China. A Recent report showed that Yukmijihwang-
tang was ranked first in consumption in the Korean herbal
medicine market [11]. In China, the annual market turn-
over of Yukmijihwang-tang in herbal medicine is about US
$633 million [12]. Traditionally, Yukmijihwang-tang is
applied in treating renal disorders, diabetes mellitus,
and neurosis [13]. There have been many studies on the
pharmacological effects of Yukmijihwang-tang, such as
protection against renal ischemia/reperfusion [14], mem-
ory enhancement [15], stimulation of spermatogenesis
[16], inhibition of bone loss [17], anti-asthmatic effects
[18] and antidiabetic effects [13]. Although many research-
ers have investigated the pharmacological effects of
Yukmijihwang-tang, there has been no study on its pos-
sible protective effects against BPH.
Therefore, this study investigated the effects of an aque-
ous extract of Yukmijihwang-tang (YJT) on testosterone-
induced BPH in rats by measuring prostate weight
changes and the DHT levels in the serum and prostate, by
western immunoblotting and histomorphology.Methods
Preparation of Yukmijihwang-tang
The Yukmijihwang-tang formula was prepared in our la-
boratory from a mixture of chopped crude herbs pur-
chased from Omniherb (Yeongcheon, Korea) and HMAX
(Chungbuk, Korea). Before performing the study, identity
of each crude herb was confirmed by Professor Je-Hyun
Lee at the Oriental College of Dongguk University
(Gyeongju, Korea). Yukmijihwang-tang was prepared as
described in Table 1 and extracted in distilled water at
100°C for 2 h. The extract was then evaporated to dryness
and freeze-dried (yield: 27.0%). An analysis of the chemical
contents of YJT was conducted using high performance li-
quid chromatography (HPLC) system in our previous
study [12]. The chemical standards used to identify andTable 1 Composition of YJT
Scientific name Amount (g) Company
of purchase
Source
Rehmannia glutinosa 8.0 Omniherb Kunwi, Korea
Cornus officinalis 4.0 Omniherb Gurye, Korea
Dioscorea batatas 4.0 Omniherb Kunwi, Korea
Paeonia suffruticosa 3.0 HMAX China
Poria cocos 3.0 Omniherb Yeongcheon, Korea
Alisma orientale 3.0 Omniherb Imsil, Korea
Total 25.0quantitate compounds in the YJT included the following:
5-hydroxymethyl-2-furaldehyde (5-HMF) as a component
of Rehmannia glutinosa, loganin of Cornus officinalis, and
paeoniflorin and paeonol of Paeonia suffruticosa. The
concentration of chemicals in YJT were measured as
the following: 5-HMF 3.70 ± 0.11 mg/g, loganin 1.77 ±
0.05 mg/g, paeoniflorin 1.08 ± 0.03 mg/g, and paeonol
1.98 ± 0.02 mg/g.
Animals
Male 12-week-old Wistar rats (n=30) weighing 250 – 350 g
(Central Lab. Animal. Inc., Seoul, Korea) were housed in a
room maintained at 18–23°C and at a relative humidity
of 40–60% with an alternating 12 /12 h light/dark cycle.
They were offered a standard laboratory diet and water
ad libitum. All experimental procedures were carried
out in accordance with the NIH Guidelines for the Care
and Use of Laboratory Animals and were approved by
Korea Institute of Oriental Medicine Institutional Ani-
mal Care and Use Committee. The animals were cared
for in accordance with the dictates of the National Ani-
mal Welfare Law of Korea.
Experimental procedures
BPH was induced by subcutaneous injection of testoster-
one propionate (TP, 3 mg/kg, Tokyo Chemical Ins. Co.,
Tokyo, Japan) for 4 weeks. After 1 week of acclimatization,
the rats were divided into five groups: (A) a normal con-
trol group that received phosphate-buffered saline (PBS, p.
o.) with corn oil (s.c.); (B) a BPH group that received PBS
(p.o.) with TP (s.c.); (C) a positive control group that
received finasteride (10 mg/kg, p.o.) with TP (s.c.); and (D
and E) YJT groups that received YJT at 200 or 400 mg/kg
(p.o.), respectively, with TP (s.c.). Finasteride, a 5α-reductase
inhibitor, was used as a positive anti-BPH drug and was pur-
chased from Sigma-Aldrich (St Louis, MO, USA). Its effect-
ive dose for treating BPH was determined based on a
previous study [19]. All materials were administered to ani-
mals once daily for 4 weeks, and body weight was measured
weekly. The application volumes were 5 mL/kg for oral ad-
ministration (PBS, finasteride and YJT) and 3 mL/kg for
subcutaneous injection (corn oil and TP) and were calcu-
lated in advance based on the most recently recorded body
weights of individual animals. After the last treatment, all
animals were fasted overnight and euthanized using pento-
barbital at 100 mg/kg body weight injected intraperitoneally
(Han Lim Pharmaceutical. Co. Ltd., Yongin, Korea). Blood
samples were drawn from the caudal vena cava, and the
serum was separated by centrifugation. Serum was stored at
at −80°C for hormone assays. The prostates were removed
immediately and weighed. Relative prostate weight was cal-
culated as the ratio of prostate weight to body weight. The
percentage inhibition of the increase in prostate weight
induced by YJT was determined according to previous study
Table 2 Effects of YJT on body weights and prostate weights
Groups Prostate weights % Inhibition Body weights (g)
Absolute (g) Relative (g) Initial Final
NC 1.44 ± 0.10 0.35 ± 0.02 273.5 ± 8.50 416.7 ± 12.75
BPH 3.05 ± 0.55## 0.78 ± 0.15## 273.9 ± 8.94 391.5 ± 23.47
Finasteride 1.95 ± 0.28** 0.51 ± 0.04** 62.01% 276.0 ± 13.01 380.3 ± 46.58
YJT-200 2.14 ± 0.25** 0.54 ± 0.06** 54.48% 277.2 ± 13.08 394.2 ± 27.11
YJT-400 2.25 ± 0.27** 0.56 ± 0.10** 50.79% 278.9 ± 9.34 404.8 ± 26.01
NC: corn oil injection (s.c) + PBS (p.o.), BPH: testosterone (s.c) + PBS (p.o.), Finasteride: testosterone (s.c) + finasteride (10 mg/kg, p.o.), YJT-200 and −400:
testosterone (s.c) + YJT (200 and 400 mg/kg, respectively, p.o.).
## P< 0.01 when compared with the NC group.
** P< 0.01 when compared with the BPH group.
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One half was fixed using 10% neutral-buffered formalin and
embedded in paraffin for histomorphology and the other
was stored at −80°C for other analyses.
Preparation of prostate homogenates
Prostatic tissue was homogenized (1/10 w/v) in tissue
lysis/extraction reagent containing protease inhibitors
(Sigma-Aldrich) using an IKA T10 Basic (IKA Works,
Staufen, Germany). Homogenates were centrifuged at
12,000 g for 25 min at 4°C. Protein concentrations in the
supernatant fractions were determined using Bradford
reagent (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Measurement of DHT levels in the serum and prostate
Levels of DHT in serum and the prostate were deter-
mined using an enzyme-linked immunosorbent assay
(ELISA) kit according to the manufacturer’s instructions
(ALPCO Diagnostics, Salem, NH, USA). The absorbanceFigure 1 Effects of YJT on DHT levels in the serum. NC: corn oil
(s.c.) + PBS (p.o), BPH: testosterone (s.c.) + PBS (p.o.), Fin:
testosterone (s.c.) + finasteride (10 mg/kg, p.o.), YJT-200, 400:
testosterone (s.c.) + YJT (200 or 400 mg/kg, respectively, p.o).
##Significant difference at p< 0.01 compared with the NC group. *,
**Significant difference at P< 0.05 and P< 0.01compared with the
BPH group, respectively.was measured at 450 nm using a microplate ELISA
reader (Bio-Rad Laboratories, Inc.). Values are expressed
per mg protein for the prostate and per mL for serum.Western blotting
Equal aliquots (30 μg) of total lung protein were heated at
100°C for 5 min then loaded onto 12% SDS−PAGE gels,
followed by transfer to nitrocellulose membranes at 100 V
for 2 h. The membranes were blocked for 1 h with Tris-
buffered saline containing 0.05% Tween-20 (TBST) plus
5% skim milk and were incubated with anti-proliferating
cell nuclear antigen (anti-PCNA, 1:1000 dilution; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and anti-
β-actin (1:1000 dilution; Cell Signaling Technology,
Danvers, MA, USA) overnight at 4°C. The membranes
were washed three times with TBST and then incubated
with a 1:10,000 dilution of horseradish peroxidase-
conjugated secondary antibody (Jackson ImmunoResearch,
West Grove, PA, USA) for 1 h at room temperature. TheFigure 2 Effects of YJT on the DHT levels in the prostate. NC:
corn oil (s.c.) + PBS (p.o), BPH: testosterone (s.c.) + PBS (p.o.), Fin:
testosterone (s.c.) + finasteride (10 mg/kg, p.o.), YJT-200, 400:
testosterone (s.c.) + YJT (200 or 400 mg/kg, respectively, p.o).
##Significant difference at P< 0.01 compared with the NC group.
**Significant difference at P< 0.01 compared with the BPH group.
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and were then developed using an enhanced chemilumin-
escence kit (Amersham Biosciences, Little Chalfont, UK).
For quantitative anlaysis, band densities were determined
using Chemi-Doc (Bio-Rad Laboratories, Inc.).Histomorphology
Fixed prostate tissue embedded in paraffin wax were cut
into 4 μm thick sections and stained with hematoxylin
(Sigma-Aldrich MHS-16) and eosin (Sigma-Aldrich
HT110-1-32). The sections were mounted and cover-
slipped using mounting medium (Invitrogen, Carlsbad,
CA, USA) and then examined under a microscope
(Nikon, Tokyo, Japan). Measurement of prostate epithe-
lial thickness was performed using an image analyzer
(Molecular Devices Inc., CA, USA).Statistical analysis
Data are expressed as the means ± standard deviation
(S.D.). Statistical significance was determined using ana-
lysis of variance. When tests showed a significant differ-
ence among groups, data were analyzed further using aFigure 3 Effects of YJT on the expression of PCNA protein. (A) Image
β-actin). NC: corn oil (s.c.) + PBS (p.o), BPH: testosterone (s.c.) + PBS (p.o.), F
testosterone (s.c.) + YJT (200 or 400 mg/kg, respectively, p.o). #Significant d
difference at P< 0.05 compared with the BPH group.multiple comparison procedure and Dunnett’s test. The
significance levels were set at P< 0.05 and< 0.01.
Results
Effect of YJT on prostate weights
Rat in the BPH group showed absolute and relative pros-
tate weights that were significantly greater than those of
rats in the normal control group, whereas prostate
weights in the finasteride-treated group were decreased
markedly compared with the BPH group (Table 2). YJT-
treated groups also exhibited significant decreases in abso-
lute and relative prostate weights compared with the BPH
group. In addition, YJT inhibited the TP-induced increase
in prostate weight by 54.48% in the 200 mg/kg YJT group
and by 50.79% in the 400 mg/kg YJT group. These results
were similar to those for the finasteride-treated group.
There were no significant differences in body weight
changes among groups.
Effects of YJT on DHT levels in serum
The BPH group showed a significant increase in serum
DHT level (356.5 ± 33.30 pg/mL, P< 0.01) compared
with the normal control group (161.38 ± 32.09 pg/mL;on the gel, (B) Relative units of PCNA expression (ratio of PCNA to
in: testosterone (s.c.) + finasteride (10 mg/kg, p.o.), YJT-200, 400:
ifference at p< 0.05 compared with the NC group. *Significant
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showed a significantly reduced serum DHT level
(236.6 ± 29.88 pg/mL, P< 0.01) compared with the BPH
group. Similarly to finasteride-treated group, the YJT-
treated groups showed significant reduction in DHT
levels (233.4 ± 52.53 pg/mL in the 200 mg/kg group,
P< 0.01; 275.3 ± 40.79 pg/mL in the 400 mg/kg group,
P< 0.05) compared with the BPH group.
Effects of YJT on DHT levels in the prostate
The DHT level in the prostates of the BPH group
(547.6 ± 140.84 pg/mg protein, P< 0.01) was markedly
higher than in the negative normal controls (Figure 2).
However, prostatic DHT level in the finasteride-treated
group (315.5 ± 17.98 pg/mg protein, P< 0.01) was sig-
nificantly lower than in the BPH group. Prostatic DHT
levels in the YJT-treated rats were 308.0 ± 42.93 pg/mg
protein in the 200 mg/kg group and 343.6 ± 49.57 pg/mL
in the 400 mg/kg group, which were significantly less
than the level in the BPH group.
Effects of YJT on PCNA expression in the prostate
The expression of PCNA protein increased in the BPH
group compared with the normal control group andFigure 4 Effects of YJT on prostatic hyperplasia. (A) Histomorphologica
PBS (p.o), BPH: testosterone (s.c.) + PBS (p.o.), Fin: testosterone (s.c.) + finas
400 mg/kg, respectively, p.o). ##Significant difference at P< 0.01 compared
with the BPH group.decreased in the finasteride-treated group compared
with the BPH group. Expression of PCNA protein was
also reduced in the YJT-treated groups compared with
the BPH group (Figure 3A , B).
Effects of YJT on prostatic epithelial hyperplasia
The BPH group showed prostatic epithelial hyperplasia
(Figure 4A). Finasteride-treated animals showed mild
epithelial hyperplasia compared with the BPH animals.
YJT-treated animals also showed a reduction in epithe-
lial hyperplasia compared with BPH animals, which was
similar to the reduction in finasteride-treated animals.
The BPH group showed significantly increased prostatic
epithelial thickness compared with the negative control
group; however, the YJT-treated groups and the finasteride-
treated group showed markedly reduced hyperplasia com-
pared with the BPH group (Figure 4B).
Discussion
We evaluated the inhibitory effects of YJT on the develop-
ment of BPH using TP-induced BPH in rats. Animals with
BPH induced by TP treatment showed significant
increases in absolute and relative prostate weights,
increased DHT levels in the serum and prostate andl changes of prostate, (B) Prostatic epithelial thickness. NC: corn oil (s.c.) +
teride (10 mg/kg, p.o.), YJT-200, 400: testosterone (s.c.) + YJT (200 or
with the NC group. **Significant difference at P< 0.01 compared
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PCNA expression. In contrast, the YJT-treated animals
showed significant reductions in absolute and relative
prostate weights and in DHT levels in the serum and
prostate, and mild prostatic epithelial hyperplasia with
decreased PCNA expression.
Rats with BPH showed significantly increased absolute
and relative prostate weight compared with the negative
control animals; however, YJT-treated animals showed
significant reductions in these measures compared with
the BPH animals. According to previous studies, increased
prostate weight is an important marker indicating the de-
velopment of BPH [20,21]. BPH involves epithelial and
stromal hyperplasia of the prostate, resulting in an in-
crease in the prostate weight. When sufficiently large, the
prostate constricts the urethral canal to cause partial or
sometimes complete obstruction [2]. For these reason,
many studies have tested the inhibitory effects of various
substances on the development of BPH by measuring
prostate weights [22,23]. In the results from histomor-
phology of the prostate, the rats with BPH showed epithe-
lial hyperplasia with an increase in epithelial thickness
compared with the negative control animals. In contrast,
the YJT-treated rats showed mild prostatic epithelial
hyperplasia with a reduction in epithelial thickness com-
pared with BPH animals. These results are in agreement
with the prostate weight results. In addition, we evaluated
PCNA expression in the prostate to test the inhibitory
effects of YJT on epithelial cell proliferation in rats with
TP-induced BPH. Measuring PCNA is commonly used to
evaluate cellular proliferation in benign and malignant
proliferating tissues, as the PCNA level is correlated dir-
ectly with the degree of proliferation [24,25]. Previous
studies on BPH demonstrated that PCNA is a meaningful
indicator of prostatic proliferation, and that its expression
in the prostate is significantly increased in animals with
experimentally induced BPH [26,27]. In the present study,
YJT significantly decreased PCNA expression in the
prostate compared with the BPH group, in parallel with
a reduction in the prostatic hyperplasia. Thus, YJT
treatment effectively inhibited the prostatic hyperplasia
induced by TP.
DHT, a steroid hormone produced from testosterone
by the enzyme 5α-reductase, is the primary active me-
tabolite of testosterone [28]. The role of DHT in BPH is
well known, as it is the androgen responsible for pros-
tate growth [8,29]. Because DHT has a 10 times higher
affinity for the androgen receptor than testosterone,
DHT easily binds to androgen receptors, which stimu-
lates the transcription of growth factors that are mito-
genic for the epithelial and stromal cells of the prostate
[30]. Therefore, DHT is ultimately responsible for pros-
tatic epithelial and stromal cell hyperplasia [31]. As men-
tioned above, because DHT is formed from testosteroneby 5α-reductase, many studies have focused on reducing
the DHT level by inhibiting this enzyme. Finasteride, a
5α-reductase inhibitor, is used as an elective drug for
treating human BPH [8]. In previous studies, finasteride
reduced DHT levels in the serum and prostate, inhibiting
prostate enlargement and attenuating the LUTS caused by
BPH [32,33]. However, there is limited clinical use of 5α-
reductase inhibitors including dutasteride and finasteride,
because of their adverse effects [9,10]. In the present
study, YJT-treated animals showed significant reductions
in DHT levels of the serum and prostate compared with
the BPH animals, as did the finasteride-treated rats. These
results were consistent with the changes in prostate
weights, PCNA expression levels and histomorphology.
These findings indicate that YJT suppressed the develop-
ment of BPH in this animal model, in a manner closely
associated with reductions in DHT levels. In addition, YJT
has been proved to be safe through toxicity studies
[11,12]. In particular, there was no observed adverse effect
from YJT at up to 2000 mg/kg in acute and subchronic
toxicity studies [12].Conclusion
In conclusion, YJT significantly reduced prostate weights,
prostatic hyperplasia, PCNA expression, and DHT levels
in the serum and prostates of experimental rats. These
results indicate that YJT effectively inhibits the develop-
ment of BPH. Combined with the proven safety of YJT,
these findings strongly support the feasibility of using YJT
therapeutically in treating BPH.
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